Navigation Links
Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
Date:10/31/2007

LAUSANNNE, Switzerland and CHIBA, Japan, October 31 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, and NanoCarrier Co., Ltd. (NanoCarrier) today announced the signature of a License and Supply Agreement for DACH-Platin Polymeric Micelle (Debio 0507/NC-4016), MediCelle(TM) technology, owned by NanoCarrier, currently in late preclinical development by Debiopharm for use in oncology. Phase I clinical studies are expected to start in 2008 in Europe and / or USA.

Under the terms of the agreement:

- NanoCarrier grants Debiopharm an exclusive license, with the right to sublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwide excluding Japan.

- Debiopharm will provide NanoCarrier exclusively with the starting material of DACH-platin, and NanoCarrier will manufacture and provide DACH-Platin Polymeric Micelle solely to Debiopharm.

- Debiopharm will cover costs related to the manufacture of DACH-Platin Polymeric Micelle and will pay NanoCarrier an up-front and milestones, as well as running royalties for the license.

- NanoCarrier will pay Debiopharm for the use of Debiopharm's data or intellectual property upon registration in Japan.

Debiopharm will be fully responsible for the development of DACH-Platin Polymeric Micelle. The collaboration between the two companies started in 2005, when NanoCarrier granted Debiopharm the exclusive option to license-in a DACH-platin-PEG-polyglutamic acid (DACH Platin MediCelle(TM)) from NanoCarrier, for use in oncology.

About DACH-Platin Micelle

DACH-platin is an active metabolite of Oxaliplatin, which shows stronger anticancer activity. Oxaliplatin is an anticancer drug effective against progressive and relapsed colon cancer. However, it may cause severe peripheral neuropathy like numbness. Because of its hydrophobic feature, it was difficult to formulate DACH-platin, but by using micellar nanoparticles, we believe we can develop a new, more effective DACH-platin anticancer drug with possible lower side effects.

The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent for DACH-platin micelle has been granted as Patent No. 39955992 in May 2007.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products: Eloxatin(R), Decapeptyl(R) and Trelstar(R) with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About NanoCarrier Co., Ltd.

NanoCarrier is a biotech that focuses on the research and development of drugs primarily in the field of cancer with micellar nanoparticles technology. Micellar nanoparticles (also known as polymeric micelle) are formed from biocompatible block copolymers which consist of a hydrophilic polymer, polyethyleneglycol (PEG), and a hydrophobic polymer, polyamino acid derivative.

By encapsulating drugs efficiently inside, micellar nanoparticles work as functional particles that stay in bloodstream for a long period of time and deliver drugs preferentially to targeted sites, thus minimizing unfavourable side effects and improving therapeutic efficacy. To date, two anticancer drugs have proceeded to clinical trials.


'/>"/>
SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy to Market Debiopharms New Drug in India
2. Georgia: Indian doctors license cancelled
3. US Government Licenses New Hypertension Drug
4. Proposal to license Ayurveda Practitioners in the US
5. Genomatix Licensed By Bayer Healthcare
6. Panacea Biotec In-Licenses FMD Vaccine
7. Test for Esophageal Reflux Licensed to Bayer by University
8. Thailand Goes Ahead With Licenses for Generic Drugs
9. Swedish Biotech Licenses HIV Drug to China for Development
10. More Foreign Trained Doctors Receive Licenses
11. FDA Licenses First US Vaccine Against Avian Flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, one of ... world, is pleased to release their 2015 global impact data. In 2015, DKT ... 14,000 maternal deaths and 3.8 million unsafe abortions across 21 countries worldwide. ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... ranging from medical and pharmaceutical, to food and HVAC facilities. Their knowledgeable staff ... training. , For medical applications, Afrimesure offers a variety of MadgeTech systems ...
(Date:5/25/2016)... Vallarta, Mexico (PRWEB) , ... May 25, 2016 , ... ... surrounding the restorative properties of precious stones to complement its new wellness suites ... over two floors and feature a plethora of special services and insuite amenities, from ...
(Date:5/25/2016)... , ... May 25, 2016 , ... The University of ... and Health Professions. She will lead a team of more than 100 full-time faculty ... begin her role as dean in late August. , Baker comes to USF from ...
(Date:5/25/2016)... ... ... more than fifty years, we've suffered whiplash as each new scientific study seemed to contradict ... nutritional advice – advice that was supposed to keep us healthy and slim. And what ... are considered to be overweight and more than 1 in 3 adults are considered to ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 Een app die ... zij collectief patiënten kunnen behandelen, hun kennis kunnen delen ... achter de nieuwe en revolutionaire MDLinking App, ontwikkeld door ... vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... beschikbaar is, wordt op dinsdag 24 mei officieel gepresenteerd ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
(Date:5/23/2016)... 23, 2016 Non-invasive diagnostic test ... multiple diseases; ,Technology to be presented at Yissum’s booth, ... Research Development Company of the Hebrew University of Jerusalem ... agreement with Aurum Ventures MKI, the technology investment arm of ... new diagnostic approach for early detection of multiple diseases ...
Breaking Medicine Technology: